Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89061 | 0.89 | KMT2A (0.56) | KMT2APOLBMTNR1BMTNR1ACNR1 | |
| SCHEMBL90352 | 0.88 | KMT2A (0.55) | KMT2APOLBMTNR1BMTNR1ACNR1 | |
| SCHEMBL15087924 | 0.86 | KMT2A (0.54) | KMT2APOLBMTNR1BMTNR1ACNR1 | |
| SCHEMBL1911374 | 0.86 | KMT2A (0.54) | KMT2APOLBMTNR1BMTNR1ACNR1 | |
| SCHEMBL89611 | 0.80 | TSHR (0.51) | KMT2APOLBMTNR1BMTNR1ACNR1 | |
| SCHEMBL13753200 | 0.76 | MTNR1B (0.75) | KMT2AMTNR1BMTNR1AKDM4EL3MBTL1 | |
| SCHEMBL16479313 | 0.76 | L3MBTL1 (0.53) | KMT2AMTNR1BMTNR1ACNR1CNR2 | |
| SCHEMBL13973367 | 0.76 | KMT2A (0.58) | KMT2AMTNR1BMTNR1ACNR1CNR2 | |
| SCHEMBL10683818 | 0.76 | MAPT (0.59) | MTNR1BMTNR1AKDM4EL3MBTL1 | |
| SCHEMBL11304280 | 0.75 | ALDH1A1 (0.62) | KMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | KMT2A 3129/4885POLB 589/4885MTNR1B 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.